Company News 20 Jan 2025 Orthocell receives $3.18m R&D tax incentive refund Orthocell has announced that it has received a $3.18 million R&D Tax Incentive Refund for the 2023/2024 financial year. Orthocell
Media 08 Jan 2025 Stockhead Special Report | Orthocell achieves third consecutive quarter of record revenue Orthocell has been featured in a special report on Stockhead highlighting Orthocell's consistent growth in sales of our regenerative medicine… Orthocell
Company News 08 Jan 2025 OCC Quarterly Report | Quarter ended 31 December 2024 Orthocell has recorded a third consecutive quarter of record revenue, reporting $2.21 million in the December ‘24 Quarter. Orthocell
Media 03 Jan 2025 Podcast | Talk Ya Book Orthocell Chairman John Van Der Wielen recently spoke with podcast host Chris Judd on Talk Ya Book to discuss the… Orthocell
Media 03 Jan 2025 The West Australian | Orthocell cracks a new record high Orthocell has been featured in The West Australian in an article by Sean Smith titled “Orthocell cracks a new record… Orthocell
Company News 19 Dec 2024 Orthocell Submits U.S. FDA Regulatory Application Orthocell has announced the submission of its U.S. FDA 510(k) regulatory application for clearance to commercially distribute Remplirâ„¢ into the… Orthocell
Media 16 Dec 2024 Podcast | Frazis Capital Podcast Orthocell CEO & MD, Paul Anderson, recently joined Micahel Frazis on the Frazis Capital Podcast. Orthocell
Company News 12 Dec 2024 Orthocell Achieves Major Milestone with First Sales of Remplirâ„¢ in Singapore Orthocell has today announced the achievement of first sales of Remplirâ„¢ in Singapore, marking another significant milestone in its global… Orthocell
Media 03 Dec 2024 The Australian Financial Review | Perth’s billionaires pile into medtech Orthocell Orthocell has been featured in The Australian Financial Review in an article by Health Editor Michael Smith titled “Perth’s billionaires… Orthocell
Company News 02 Dec 2024 Orthocell successfully completes US FDA 510(k) regulatory study for Remplirâ„¢ Orthocell has today reached another significant milestone with the successful completion of its Remplirâ„¢ 510(k) nerve repair regulatory study, validating… Orthocell
